NCT00192504 - Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions

Respiratory Syncytial Virus Prophylaxis

Interventions

BIOLOGICAL

Motavizumab

Single dose of Motavizumab at a dose of 3 mg/kg administered intravenously (in the vein) on Day 0

BIOLOGICAL

Motavizumab

Single dose of Motavizumab at a dose of 15 mg/kg administered intravenously (in the vein) on Day 0

BIOLOGICAL

Motavizumab

Single dose of Motavizumab at a dose of 30 mg/kg administered intravenously (in the vein) on Day 0

OTHER

Placebo

Single dose of placebo administered intravenously (in the vein) on Day 0